Statement: Cohort 1 and 2 of the primary trial recorded the same number of patients with Febrile Neutropenia.
Primary_evidence: Adverse Events 1:   Total: 5/41 (12.20%)   Neutropenia  4/41 (9.76%)   Febrile Neutropenia  0/41 (0.00%)   SGPT (ALT)  1/41 (2.44%) Adverse Events 2:   Total: 5/40 (12.50%)   Neutropenia  4/40 (10.00%)   Febrile Neutropenia  1/40 (2.50%)   SGPT (ALT)  0/40 (0.00%)